Medinet to Commercialize Cancer Technology Using MaxCyte's Cell Loading System
Posted on: Thursday, 21 August 2008, 09:01 CDT
MaxCyte and Medinet have announced that Medinet will begin commercializing a novel cell engineering approach, utilizing MaxCyte's cell loading technology, on its cancer immunotherapy services in Japan.
The new approach to cancer immunotherapy is expected to achieve increased efficacy compared to the method which Medinet has been providing.
In August 2007, both parties signed an exclusive license, development and supply agreement to use MaxCyte's proprietary cell loading system to support clinical studies and commercialization of Medinet's cancer immunotherapy service in Japan.
Under terms of the agreement, MaxCyte provides the exclusive right to utilize its proprietary technology in the closed-system manufacturing of Medinet's immuno-cell therapy service in multiple cell processing centers across Japan.
Source: Datamonitor
Related Articles
- Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018
- Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017
- Medinet Starts Commercialization of Novel Cancer Immunotherapy Technology in Japan Utilizing MaxCyte's Cell Loading System
- New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
- Binex and MaxCyte Collaborate on Cancer Immunotherapy Research
- Introgen's P53 Immunotherapy Drug Candidate to Advance Into Second Phase 2 Clinical Trial in Small Cell Lung Cancer With National Cancer Institute
- Introgen Announces Positive Phase 2 Clinical Trial Results With INGN 225 Immunotherapy in Patients With Small Cell Lung Cancer
- Lentigen Corporation Receives Grant From NIH to Evaluate the Use of Lentiviral-Engineered T-Cells for Cancer Immunotherapy Directed Against Key Tumor Antigen
- Dendritic Cell, the Immunotherapeutic Cell for Cancer
 |
 |
User Comments (0)
RSS Feeds